Location: United States, New Jersey, Cranbury
Total raised: $25.75M
Investors 1
| Date | Name | Website |
| - | Horizon Te... | horizontec... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.12.2016 | - | $16.5M | - |
| 04.08.2016 | - | $9.25M | - |
Mentions in press and media 20
| Date | Title | Description |
| 21.06.2024 | Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds | CRANBURY, N.J., June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate... |
| 15.05.2024 | Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update | Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P |
| 02.05.2024 | Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity | Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar year-end 2024 Hosting virtual KOL event "Beyond GLPs" on May 8, 2024 Focus will be on Company's metabolic program and the multipl... |
| 20.01.2023 | New Jersey-based biopharma startup Palatin Technologies raises USD 4.7 million in dilutive funding | CRANBURY, New Jersey, January 18, 2023 — Palatin Technologies, Inc. (NYSE American: PTN), the biopharmaceutical company developing first-in-class medicines based on the fact that molecules that modulate the activity of the melanocortin rece... |
| 15.11.2021 | Palatin Technologies : Reports First Quarter Fiscal Year 2022 Resultsand Provides Corporate Update - Form 8-K | Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update · Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Expected to Start December 2021 with Top-Line Results Expected in the Second Half Calend... |
| 22.07.2021 | Palatin Announces Presentation at the [email protected] Conference | |
| 08.07.2021 | Palatin Announces Adjournment of Annual Meeting of Stockholders | |
| 29.06.2021 | Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease | |
| 28.06.2021 | Palatin Announces New Additions to Its Senior Leadership Team | |
| 10.06.2021 | Palatin Announces Adjournment of Annual Meeting of Stockholders |
Show more